Welcome to
On Feet Nation
joseph75pe Online
Harry Online
SpaDeals123 Online
Posted by joseph75pe on August 4, 2024 at 3:15am 0 Comments 0 Likes
The global Allergy Diagnostics And Therapeutics Market size was estimated at USD 58.31 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 8.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing incidences of allergic diseases, coupled with demand for advanced therapeutics, is expected to drive the market growth in the coming years. According to estimates published by the American Academy of Allergy Asthma & Immunology (AAAAI), allergic rhinitis affects approximately 10-30% of the global population, thereby impacting the adoption of allergy therapeutics globally.
The increasing integration of technologically advanced products, such as the use of artificial intelligence technology to advance treatment outcomes and manage diseases, helps practitioners in the decision-making process. Furthermore, the rising adoption of mHealth apps for diagnosing allergies such as rhinitis is expected to boost the market. For instance, the MASK-Air app is dedicated specifically to allergic rhinitis.
Monoclonal antibodies are anticipated to contribute to the development of new therapies that eradicate specific allergy concerns, owing to their higher efficacy, long-term tolerability, and safety. Hence, key companies are developing novel & effective biologic-based therapies designed with target-specific mechanisms directed toward selective targets, especially monoclonal antibodies. In addition, consistent product approvals of highly significant monoclonal antibodies for allergy disorders are anticipated to expand the scope for growth.
New therapies such as anti-immunoglobulin E (IgE) antibodies, cytokine modulators, and DNA vaccinations are being used to treat allergic disorders. Omalizumab is a recombinant humanized IgG1 monoclonal anti-IgE antibody, which is used for treating allergic chronic urticaria and asthma. In April 2021, Genentech (Roche Group) announced that its prefilled syringe for self-injection has received FDA approval for Xolair (omalizumab) in the U.S. for chronic idiopathic urticaria allergic asthma, and nasal polyps.
The allergy diagnostics & therapeutics market is moderately competitive, with a strong presence of notable companies such as Merck & Co., Inc, Thermo Fisher Scientific, Inc., Abbott, and Pfizer, Inc. These players are undertaking various initiatives to increase their capabilities, expand their product portfolios, and improve their competencies.
Related Press Release@ Allergy Diagnostics And Therapeutics Market Report
Allergy Diagnostics And Therapuetics Market Report Highlights
List of Key Players in Allergy Diagnostics And Therapuetics Market
Request A Free Consultation@ https://www.grandviewresearch.com/request-free-consultation/1759/rfc
Allergy Diagnostics And Therapuetics Market Segmentation
Grand View Research has segmented the global allergy diagnostics & therapeutics market report on the basis of type, allergen type, test type, and region:
Allergy Diagnostics And Therapuetics Type Outlook (Revenue, USD Million, 2018 - 2030)
Allergy Diagnostics And Therapuetics Allergen Type Outlook (Revenue, USD Million, 2018 - 2030)
Allergy Diagnostics And Therapuetics Test Type Outlook (Revenue, USD Million, 2018 - 2030)
Allergy Diagnostics And Therapuetics Regional Outlook (Revenue, USD Million, 2018- 2030)
© 2024 Created by PH the vintage. Powered by
You need to be a member of On Feet Nation to add comments!
Join On Feet Nation